http://www.haematologica.org/content/early/2019/09/17/haematol.2019.2341...
This report is pre-publication and not widely released yet.
It summarizes observations in patients who have kinase mutations and were able to achieve treatment free remission (TFR) at the same rates as other CML patients without KD mutations. TFR in these KD cases were observed when patients were forced to stop therapy due to adverse events. 50% of them never lost remission. This is exciting news for those who may have failed a previous therapy and had to move to another TKI. The data listed is not statistical (not enough patients), but the observations are encouraging.
A key observation is that once a patient no matter the KD status achieves deep molecular remission ("undetected") for several years, the chance of TFR success is the same for them as for any other CML patient. I find this very interesting and good news.